card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Bridging the Gap in Liquid Biopsies with CTCs and ctDNA

Illumina TruSight Oncology 500 ctDNA Assay
Home / Insights / Bridging the Gap in Liquid Biopsies with CTCs and ctDNA

Epic Sciences’ multi-technology approach offers Comprehensive Cancer Profiling, measuring CTCs and ctDNA TSO500 from a single blood draw. CTCs and ctDNA liquid biopsies enable complementary information for clinical decisions, allowing for diagnosis, accurate prognosis, therapeutic target selection, as well as monitoring response and resistance to treatment.

Their enrichment-free approach with the CTC rare cell detection platform reveals both genotype and phenotype, providing a unique view into disease heterogeneity. Epic Sciences’ partners with biopharma companies to improve drug development with CTC technology and ctDNA TSO500 analysis for a liquid biopsy that is both minimally invasive and highly accurate.

This presentation covers:

  • How a multi-technology approach including CTCs and ctDNA TSO500 from a single blood draw can improve drug development efforts for biopharma companies.
  • How Comprehensive Cancer profiling can provide insight into patient identification using CTCs and ctDNA TSO500 biomarker analysis in lieu of difficult to obtain tissue biopsy.
  • Expanded clinical applications, including how Comprehensive Cancer Profiling can identify emerging resistant mechanisms and whether those are targetable by approved drugs or eligible for clinical trials.

Download the presentation slides or watch the recorded webinar.